<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id><journal-id journal-id-type="pmc-domain-id">2282</journal-id><journal-id journal-id-type="pmc-domain">frontpediatrics</journal-id><journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id><journal-title-group><journal-title>Frontiers in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2296-2360</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10275409</article-id><article-id pub-id-type="pmcid-ver">PMC10275409.1</article-id><article-id pub-id-type="pmcaid">10275409</article-id><article-id pub-id-type="pmcaiid">10275409</article-id><article-id pub-id-type="pmid">37334223</article-id><article-id pub-id-type="doi">10.3389/fped.2023.1189478</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pediatrics</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Efficacy and safety of ketamine for neonatal refractory status epilepticus: case report and systematic review</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Pin</surname><given-names initials="JN">Jacopo Norberto</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2201032/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leonardi</surname><given-names initials="L">Letizia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1862987/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nosadini</surname><given-names initials="M">Margherita</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/135258/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cavicchiolo</surname><given-names initials="ME">Maria Elena</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1049259/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guariento</surname><given-names initials="C">Chiara</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zarpellon</surname><given-names initials="A">Anna</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perilongo</surname><given-names initials="G">Giorgio</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/686020/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Raffagnato</surname><given-names initials="A">Alessia</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Toldo</surname><given-names initials="I">Irene</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/135225/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baraldi</surname><given-names initials="E">Eugenio</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1397770/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sartori</surname><given-names initials="S">Stefano</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/135361/overview"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><addr-line>Department of Women&#8217;s and Children&#8217;s Health, Paediatric Neurology and Neurophysiology Unit</addr-line>, <institution>University Hospital of Padua</institution>, <addr-line>Padova</addr-line>, <country>Italy</country></aff><aff id="aff2"><label><sup>2</sup></label><addr-line>Master in Pediatrics and Pediatric Subspecialties</addr-line>, <institution>University Hospital of Padua</institution>, <addr-line>Padova</addr-line>, <country>Italy</country></aff><aff id="aff3"><label><sup>3</sup></label><addr-line>Neuroimmunology Group</addr-line>, <institution>Paediatric Research Institute &#8220;Citt&#224; della Speranza&#8221;</institution>, <addr-line>Padova</addr-line>, <country>Italy</country></aff><aff id="aff4"><label><sup>4</sup></label><addr-line>Department of Women&#8217;s and Children&#8217;s Health, Neonatal Intensive Care Unit</addr-line>, <institution>University Hospital of Padua</institution>, <addr-line>Padova</addr-line>, <country>Italy</country></aff><aff id="aff5"><label><sup>5</sup></label><addr-line>Department of Women&#8217;s and Children&#8217;s Health, Child and Adolescent Neuropsychiatric Unit</addr-line>, <institution>University Hospital of Padua</institution>, <addr-line>Padova</addr-line>, <country>Italy</country></aff><aff id="aff6"><label><sup>6</sup></label><addr-line>Department of Neuroscience</addr-line>, <institution>University Hospital of Padua</institution>, <addr-line>Padova</addr-line>, <country>Italy</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Sara Matricardi, University of Studies G. d'Annunzio Chieti and Pescara, Italy</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Giada Giovannini, Azienda Ospedaliera Universitaria di Modena, Italy</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Jacopo Norberto Pin <email>pinjacopo@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">427660</issue-id><elocation-id>1189478</elocation-id><history><date date-type="received"><day>19</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>17</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-19 11:25:18.863"><day>19</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 Pin, Leonardi, Nosadini, Cavicchiolo, Guariento, Zarpellon, Perilongo, Raffagnato, Toldo, Baraldi and Sartori.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Pin, Leonardi, Nosadini, Cavicchiolo, Guariento, Zarpellon, Perilongo, Raffagnato, Toldo, Baraldi and Sartori</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fped-11-1189478.pdf"/><abstract><sec><title>Background</title><p>Evidence-based data on treatment of neonatal status epilepticus (SE) are scarce. We aimed to collect data on the efficacy and safety of ketamine for the treatment of neonatal SE and to assess its possible role in the treatment of neonatal SE.</p></sec><sec><title>Methods</title><p>We described a novel case and conducted a systematic literature review on neonatal SE treated with ketamine. The search was carried out in Pubmed, Cochrane, Clinical Trial Gov, Scopus and Web of Science.</p></sec><sec><title>Results</title><p>Seven published cases of neonatal SE treated with ketamine were identified and analyzed together with our novel case. Seizures typically presented during the first 24&#8197;h of life (6/8). Seizures were resistant to a mean of five antiseizure medications. Ketamine, a NMDA receptor antagonist, appeared to be safe and effective in all neonates treated. Neurologic sequelae including hypotonia and spasticity were reported for 4/5 of the surviving children (5/8). 3/5 of them were seizure free at 1&#8211;17&#8197;months of life.</p></sec><sec><title>Discussion</title><p>Neonatal brain is more susceptible to seizures due to a shift towards increased excitation because of a paradoxical excitatory effect of GABA, a greater density of NMDA receptors and higher extracellular concentrations of glutamate. Status epilepticus and neonatal encephalopathy could further enhance these mechanisms, providing a rationale for the use of ketamine in this setting.</p></sec><sec><title>Conclusions</title><p>Ketamine in the treatment of neonatal SE showed a promising efficacy and safety profile. However, further in-depth studies and clinical trials on larger populations are needed.</p></sec></abstract><kwd-group><kwd>ketamine</kwd><kwd>refractory status epilepctius (RSE)</kwd><kwd>neonatal status epilepticus</kwd><kwd>neonatal seizure treatment</kwd><kwd>antiseizure medication response</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="77"/><page-count count="0"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pediatric Neurology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Status epilepticus (SE) is defined as a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms which lead to abnormally prolonged seizures (after time point t1, which in the case of convulsive SE is at 5&#8197;min). SE can have long-term consequences (after time point t2, that for convulsive SE is after 30&#8197;min), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on seizure type and duration (<xref rid="B1" ref-type="bibr">1</xref>). Status epilepticus that persists despite administration of at least 2 appropriately dosed antiseizure medications including a benzodiazepine is referred to as refractory status epilepticus (RSE) (<xref rid="B2" ref-type="bibr">2</xref>).</p><p>The definition of SE used in adults is only partially applicable to neonates; a widely accepted definition describes neonatal SE as a seizure lasting thirty minutes or a series of seizures whose total duration exceeds 50% of electroencephalography (EEG) record (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Neonatal seizures are a common emergency with an incidence that ranges between 0.95&#8211;3.5/1,000 for term newborns and 10&#8211;130/1,000 live births for preterms (<xref rid="B5" ref-type="bibr">5</xref>&#8211;<xref rid="B7" ref-type="bibr">7</xref>). SE is reported in 8%&#8211;43% of newborns with seizures (<xref rid="B8" ref-type="bibr">8</xref>&#8211;<xref rid="B10" ref-type="bibr">10</xref>). The main aetiologies of neonatal seizures are fully described in <xref rid="s8" ref-type="sec">Supplementary Table S1</xref> (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B11" ref-type="bibr">11</xref>). It is debated if all neonatal seizures should be treated due to the potential side effects of antiseizure medications (ASMs). Besides, in the absence of evidence-based studies on neonatal population, numerous attempts are made to use ASMs whose efficacy has already been established in adults (<xref rid="B12" ref-type="bibr">12</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>).</p><p>In this respect, there is increasing interest towards the use of ketamine. Little is known regarding dosing, safety, and efficacy for the treatment of neonatal SE and its use is still rare.</p><p>The aim of this study was to report the case of a newborn with hypoxic-ischemic encephalopathy (HIE) who developed a RSE successfully treated with ketamine and to review the literature, providing an up-to-date summary of the available evidence on the use of ketamine for the treatment of neonatal RSE.</p></sec><sec id="s2"><title>Materials and methods</title><p>We described a case of RSE successfully treated with ketamine in a newborn with HIE.</p><p>We then performed a systematic literature review on the use of ketamine in neonatal status epilepticus. The search was carried out in Pubmed, Cochrane, Clinical Trial Gov, Scopus and Web of Science by two researchers (LL and JNP), up-to-date to December 2022 (<xref rid="F1" ref-type="fig">Figure&#160;1</xref>), complying with the PRISMA guidelines.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>Identification of studies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fped-11-1189478-g001.jpg"/></fig><p>The search terms used were (((newborn) AND (seizure)) AND (ketamine)), (((newborn) AND (status epilepticus)) AND (ketamine)), ((neonatal seizure) AND (ketamine)). We also considered clinicaltrial.gov for ongoing trials. No language restrictions were applied. The available articles were filtered manually for patients in neonatal age (&#8804;1&#8197;month of life) with SE treated with ketamine. Demographics, clinical, diagnostic and treatment data were collected. Studies with mixed population (neonates, children and adults) without a clear division by age groups, or reviews not reporting data on new patients, were excluded. Studies in which ketamine was not used as an ASM were excluded.</p></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3a"><title>Case report</title><p>A male infant was born at 40&#8201;+&#8201;3/7 gestational weeks, after an uneventful pregnancy. There was no relevant family history. Labor and vaginal delivery were uncomplicated, except for meconium-stained amniotic fluid. Birth weight, head circumference and length were all appropriate for gestational age. At birth, he was hypotonic, without spontaneous respiratory activity. Heart rate was stably &gt;100 beats per minute. T-piece ventilation was immediately started followed by nasotracheal intubation at 10&#8197;min of life, with subsequent rapid improvement of activity and tone. At 19&#8197;min of life the newborn was extubated, showing good spontaneous respiratory activity and blood saturation values. Apgar scores were 6, 7, 7 and 8 at 1&#8242;, 5&#8242;, 10&#8242; and 15&#8242;, respectively. Venous cord blood pH was 7.30, pCO2 31.3&#8197;mmHg and base deficit of &#8722;11.8&#8197;mmol/L. At 1&#8197;h of life, arterial blood gas analysis showed metabolic acidosis (pH 7.03, HCO3 13.8&#8197;mmol/L, BE &#8722;16.9&#8197;mmol/L), but since Sarnat and Sarnat score was 0, therapeutic hypothermia was not started. At 18&#8197;h of life, the baby presented apnoeic episodes with desaturation followed by bilateral clonic jerks. He was transferred to a hub hospital, where continuous electroencephalography (EEG) recording revealed multifocal seizures. At 36&#8197;h of life cerebral magnetic resonance imaging (MRI) showed abnormal diffusion restriction in fronto-temporal-parietal cortical/subcortical regions and thalamus bilaterally. Metabolic and genetic (array-comparative genomic hybridization (aCGH) and epilepsy comprehensive panel were performed) aetiologies were investigated and excluded. The boy soon developed a refractory status epilepticus (RSE): seizures were resistant to phenobarbital (max dose 40&#8197;mg/kg/die), levetiracetam (70&#8197;mg/kg/die), phenytoin (10&#8197;mg/kg/die), midazolam (1&#8197;mg/kg/h), lidocaine (7&#8197;mg/kg/h, for 36&#8197;h) and vitamin B6 (100&#8197;mg/kg bolus, then 15&#8197;mg/kg/die). Thiopental (5&#8197;mg/kg/h) made it possible to control clinical epileptic seizures, with persistence of electrical seizures. At the age of 8&#8197;days, he was referred to our neonatal intensive care unit. With informed consent, he was started on ketamine at 10&#8197;mcg/kg/min, with continued EEG and vital signs monitoring. Ketamine was titrated up to 100&#8197;mcg/kg/min in order to control the electro-clinical seizures. It was therefore possible to gradually discontinue all other ASMs and sedative drugs. Ketamine was administered for a total of 8&#8197;days. No side effects were reported. At 2&#8197;weeks of life, cerebral MRI showed diffuse white matter oedema with concomitant bilateral necrotic evolution of previously found lesions. Proton spectroscopy study of the right nucleocapsular region showed an elevated lactate peak consistent with hypoxic-ischemic injury.</p><p>Due to severe neurological impairment, extensive brain damage and absence of spontaneous respiratory activity, a palliative care pathway was started in agreement with the parents. The baby died at 23&#8197;days of life.</p></sec><sec id="s3b"><title>Literature review</title><p>The literature search yielded a total of 214 articles (<xref rid="F1" ref-type="fig">Figure&#160;1</xref>). 54 records were excluded because they were duplicates. 133 additional records were excluded after title and abstract examination: 12 studies including only adults or children older than 1 month, 99 studies not related to neonatal SE, 22 studies made on animals or <italic toggle="yes">in vitro</italic>. A total of 27 full-text articles were assessed for eligibility. After full-text examination, 20 more studies were excluded: 6 reviews not reporting raw data (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B18" ref-type="bibr">18</xref>), 2 articles not reporting data on neonates (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>), 2 studies without a clear division by age groups (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>), 1 article in which ketamine was not mentioned (<xref rid="B23" ref-type="bibr">23</xref>). Ketamine was not used as ASM in 5 studies (<xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B28" ref-type="bibr">28</xref>); 1 trial that was prematurely halted (<xref rid="B29" ref-type="bibr">29</xref>) and 2 correspondence letters (over one of the case reports already included) were excluded (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). A final number of 7 studies were included (<xref rid="B32" ref-type="bibr">32</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>), (<xref rid="F1" ref-type="fig">Figure&#160;1</xref>). The articles were analyzed and described below and in <xref rid="T1" ref-type="table">Table&#160;1</xref>. We also considered our case report, for a total of 8 neonatal cases included. Of the neonates included, six out of eight were born at term, one was born at 34 gestational weeks (<xref rid="B35" ref-type="bibr">35</xref>), and in one case gestational age was not reported (<xref rid="B32" ref-type="bibr">32</xref>). We did not notice a gender prevalence. Six out of eight neonates were born from uncomplicated, uneventful pregnancies. In one case prenatal diagnosis of Pierre-Robin syndrome associated with lissencephaly and polymicrogyria was made. For one case data were not available (<xref rid="B32" ref-type="bibr">32</xref>). Perinatal history of respiratory failure and/or hypotonia was present in 6/7 cases. In one case perinatal history was not available (<xref rid="B38" ref-type="bibr">38</xref>). Onset of symptoms occurred during the first 24&#8197;h of life (6/8), except for two cases, whose first symptoms started within the third day of life. At clinical presentation signs and symptoms included seizures (8/8), apnoea and desaturation (6/8). EEG was performed in all cases. Burst suppression pattern was the most frequent finding at presentation (5/8), often associated with multifocal seizures (3/8).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Summary of evidences.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">&#160;</th><th valign="top" align="center" colspan="3" rowspan="1">Demographic</th><th valign="top" align="center" colspan="4" rowspan="1">Diagnosis</th><th valign="top" align="center" colspan="8" rowspan="1">Antiseizure medications</th><th valign="top" align="center" colspan="3" rowspan="1">Outcomes</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">Sex</td><td valign="top" align="center" rowspan="1" colspan="1">Gestational age (weeks)</td><td valign="top" align="center" rowspan="1" colspan="1">5&#8197;min Apgar</td><td valign="top" align="center" rowspan="1" colspan="1">Onset symptoms</td><td valign="top" align="center" rowspan="1" colspan="1">Age at presentation (days)</td><td valign="top" align="center" rowspan="1" colspan="1">Brain imaging</td><td valign="top" align="center" rowspan="1" colspan="1">Diagnosis</td><td valign="top" align="center" rowspan="1" colspan="1">1st line</td><td valign="top" align="center" rowspan="1" colspan="1">2nd line</td><td valign="top" align="center" rowspan="1" colspan="1">3rd line</td><td valign="top" align="center" rowspan="1" colspan="1">4th line</td><td valign="top" align="center" rowspan="1" colspan="1">5th line</td><td valign="top" align="center" rowspan="1" colspan="1">6th line</td><td valign="top" align="center" rowspan="1" colspan="1">7th line</td><td valign="top" align="center" rowspan="1" colspan="1">8th line</td><td valign="top" align="center" rowspan="1" colspan="1">Efficacy of Ketamine</td><td valign="top" align="center" rowspan="1" colspan="1">Side effects</td><td valign="top" align="center" rowspan="1" colspan="1">Death</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pin 2022</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Male</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>40&#8201;+&#8201;3</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>7</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Apnea, desaturation, seizures</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>1</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>MRI: abnormal diffusion restriction bilaterally in cortical/subcortical regions and thalamus</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Hypoxic-ischemic encephalopathy</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenobarbital</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Levetiracetam</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenytoin</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Midazolam infusion</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Lidocaine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Vitamin B6</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Thiopental</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Ketamine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes, cessation</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes (23&#8197;days)</sans-serif>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mandal 2022</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Female</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Seizures</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>1</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>MRI: partial parieto- occipital hemimegalencephaly</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Partial hemi- megalencephaly</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenobarbital</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Levetiracetam</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenytoin</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Midazolam infusion</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Lacosamide</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Ketamine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Topiramate</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes, reduction</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Huntsman 2019</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Male</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>39&#8201;+&#8201;1</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>5</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Desaturation, seizures</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>1</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>MRI: large subacute infarction and hemorrhages</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Hypoxic-ischemic encephalopathy and hemorrhagic stroke</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenobarbital</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenytoin</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Midazolam infusion</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Topiramate</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Ketamine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes, cessation</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Freibauer 2018</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Male</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>38</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>4</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Apnea, desaturation, seizures</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>1</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>MRI: patchy areas of hyperintense T2 signal in the deep white matter</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>KCNQ2 related encephalopathy</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenobarbital</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenytoin</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Midazolam</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Ketamine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes, cessation</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes (37 days)</sans-serif>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tarocco 2014</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Female</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>34</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Apnea, seizures</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>1</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Epileptic encephalopathy, lissencephaly and polymicrogyria</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenobarbital</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenytoin</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Midazolam</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">]<sans-serif>Levetiracetam</sans-serif></td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Propofol</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Ketamine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Carbamazepine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes, cessation</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes (103&#8197;days)</sans-serif>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dhamija 2012</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>41&#8201;+&#8201;5</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>9</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Apnea, seizures</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>2</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>MRI: corpus callosum agenesis; immature sulcation pattern; spectroscopy with elevated glycine peak</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Non ketotic hyperglycinemia encephalopathy</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenobarbital</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Ketamine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes, cessation</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tegtmeyer 1995</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Female</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>40</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>10</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Seizures</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>1</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Non ketotic hyperglycinemia encephalopathy</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Diazepam</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Midazolam</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Ketamine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes, cessation</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Haider 1996</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Male</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Term</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>9</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Apnea, lethargy, seizures</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>3</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>CT: low attenuated areas in fronto-parietal regions</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Non ketotic hyperglycinemia encephalopathy</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenobarbital</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Phenytoin</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Ketamine</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">&#160;</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>Yes, cessation</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<sans-serif>No</sans-serif>
</td></tr></tbody></table></table-wrap><p>Phenobarbital was used as the first ASM in all except for one case that was initially treated with diazepam. In 4/8, phenytoin represented the second line treatment, usually followed by midazolam infusion or administration. In 2/8 cases levetiracetam was administered as second line treatment before phenytoin, followed by midazolam infusion as fourth line of treatment in both cases. Ketamine was chosen as second line treatment only in one case, not followed by administration of any other drugs (<xref rid="B36" ref-type="bibr">36</xref>), whereas it was used as the third or subsequent therapeutic line in the remaining 7/8 cases. Ketamine dosage ranged from 1.5&#8197;mcg/kg/h up to 100&#8197;mcg/kg/h and was administered for a total of 8&#8211;28&#8197;days. Ketamine was effective in cessation (7/8) or reduction (1/8) of seizures, inducing control of SE in all cases included. No acute side effects related to the use of ketamine were reported. Three neonates died at a mean age of 54&#177;34 days of life. After initial control of seizures, in two cases it was decided to withdraw care due to the overall poor prognosis and the patients died at 37 and 103&#8197;days of life, respectively (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). In one patient, status epilepticus reappeared after 15 days free of seizures (<xref rid="B35" ref-type="bibr">35</xref>). At follow-up (mean time 3&#8211;17&#8197;months), neurological outcomes of the remaining cases (5/8) mainly included hypotonia and poor sucking (4/5) or spasticity (3/5). In one case functional hemispherectomy led to definitive seizures cessation at 14&#8197;months of life (<xref rid="B32" ref-type="bibr">32</xref>). Three other cases were reported to have achieved complete seizure cessation by the age of 3&#8211;17&#8197;months (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Only in one case poor control of seizures was documented (<xref rid="B36" ref-type="bibr">36</xref>).</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In this study we aimed to investigate the efficacy and safety profile of ketamine for the treatment of neonatal SE. As regards the general characteristics of the cases included, neonates were typically born from uncomplicated pregnancies. Despite this, in most cases perinatal history of hypotonia or respiratory failure at birth was documented, most likely due to a hypoxic injury at the moment of delivery. All patients presented with seizures, whose onset was during the first 24&#8197;h of life in 75% of cases. Children whose onset of symptoms started during the next days of life were the only ones reported to be healthy at birth. We did not notice a prevalence of pre-term neonates. Timing of presentation and the absence of clear previous risk factors are in most of included cases suggestive of neonatal encephalopathy, especially of HIE (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). The gold standard for diagnosis of SE is EEG, which was performed in all cases immediately after the onset of seizures (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Recent guidelines have emphasized that EEG is required for identification, diagnosis and confirmation of neonatal seizures, including conventional EEG (cEEG) and amplitude-integrated EEG (aEEG) (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B42" ref-type="bibr">42</xref>). In contrast to this, with clinical observation alone only focal clonic and focal tonic seizures can be diagnosed if observed by an expert (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B41" ref-type="bibr">41</xref>). In most of our cases burst-suppression pattern was found, consistent with a hypoxic injury (<xref rid="B43" ref-type="bibr">43</xref>).</p><p>Currently, the most common first-line medication indicated for SE in the neonate is phenobarbital (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B44" ref-type="bibr">44</xref>&#8211;<xref rid="B46" ref-type="bibr">46</xref>). Accordingly, phenobarbital was used as the first ASM in 88% of cases, usually followed by the administration of phenytoin, midazolam or levetiracetam. Existing evidence suggests initiation with phenobarbital at the dosage of 20&#8197;mg/kg (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B42" ref-type="bibr">42</xref>). Neonates with persistence of seizures may receive an additional 20&#8197;mg/kg of phenobarbital (<xref rid="B45" ref-type="bibr">45</xref>). The only neonate that received ketamine as a second therapeutic line was affected by NKH, where ketamine is often used due to its antagonist action on the NMDARs, which are hyperactivated by the high levels of glycine. Glycine is a co-agonist of NMDAR, together with glutamate (<xref rid="B23" ref-type="bibr">23</xref>). Its excess is thought to account for the onset of seizures in neonates with NKH, but also for their long-term neurological sequelae (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>).</p><p>In all other cases (88%), ketamine was used as a third or subsequent line of treatment. It was effective in controlling RSE in all cases included. The width of the range of ketamine doses used (1.5&#8211;100&#8197;mcg/kg/h) reflects the absence of any recommendation on this topic.</p><p>SE is particularly difficult to treat in neonates: rapid neurodevelopmental mechanisms that take place in the neonatal brain result in a lower threshold for seizures. Immature neonatal brain presents a shift in the action of gamma-aminobutyric acid (GABA) from inhibition to excitation, and a greater density of NMDAR subunits, which promote prolonged excitatory postsynaptic potentials (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B49" ref-type="bibr">49</xref>&#8211;<xref rid="B51" ref-type="bibr">51</xref>). In addition to this, extracellular concentrations of glutamate are higher in neonates due to increased release and decreased reuptake at the level of the synaptic cleft (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>).</p><p>In neonates, the balance between excitatory and inhibitory forces can be additionally altered by cerebral insults such as HIE or prolonged SE itself. In fact, they all induce an upregulation and/or hyperactivation of NMDARs, an increase of glutamate expression, and a reduction in post-synaptic GABA receptors, further promoting the persistence of seizures (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p><p>Ketamine is a non-competitive NMDA glutamate receptor antagonist. NMDAR is a non-specific transmembrane cation channel made of five subunits that form a ligand and voltage gated channel. Activation of NMDAR on the post-synaptic neuronal membrane induces an influx of sodium and calcium ions that in the end results in an excitatory potential. Ketamine acts on the phencyclidine binding site present within the NMDAR channel, blocking this cations influx, and exerting its NMDAR antagonist activity (<xref rid="B55" ref-type="bibr">55</xref>).</p><p>In the mature brain, activation of GABA determines hyperpolarization of neurons thanks to a net influx of Cl<sup>&#8722;</sup> anions, resulting in an inhibitory effect (<xref rid="B56" ref-type="bibr">56</xref>). In neuroblasts and immature neurons, the presence of an inwardly directed Na<sup>+</sup>-K<sup>+</sup>-Cl<sup>&#8722;</sup> co-transporter 1 (NKCC1) determines a relatively high internal Cl<sup>&#8722;</sup> concentration. Thus, GABA receptor activation results in a net efflux of anion and cell depolarization, and explains the paradoxical excitatory effects of GABA, seen in pre-term neonates (<xref rid="B58" ref-type="bibr">58</xref>). Progressive acquisition of NKCC2 co-transporter on neurons decreases the internal chloride concentration, restoring the inhibitory GABA activity (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B57" ref-type="bibr">57</xref>&#8211;<xref rid="B59" ref-type="bibr">59</xref>).</p><p>Moreover, persistence of seizures determines the internalization inside the cell of GABA receptors that remain pharmacologically responsive only to very high doses of neurosteroids (allopregnanolone, allotetrahydrodeoxycorticosterone) or midazolam (<xref rid="B60" ref-type="bibr">60</xref>).</p><p>These mechanisms could explain the reduced efficacy of GABAergic ASMs, especially in pre-term neonates. It has been highlighted that despite correct initial loading doses of standard ASMs, more than half of neonates experience continued seizures (<xref rid="B61" ref-type="bibr">61</xref>). Key challenges in the management of this condition surround the incomplete efficacy of ASM and the concomitant higher rate of side effects with increasing dosage of GABAergic medications. In this setting, ketamine represents a viable therapeutic option in the treatment of neonatal RSE. Given the high rate of neurological sequelae expected after neonatal SE, which in older children happen in more than 50% of cases, rapid cessation of seizures should be pursued (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). After administration of ketamine, in the acute phase there was control of seizures in all cases included. However, in two cases there was recurrence of seizures (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). After a mean duration of therapy of 17.2&#8197;days, no side effects were highlighted. In contrast to this latter point, high doses of GABAergic ASMs often determine acute negative cardiovascular effects, in particular hypotension. Ketamine, owing to its sympathomimetic effects, does not necessarily require mechanical ventilation or amine administration, which have been identified as negative prognostic factors both in adults and children (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B64" ref-type="bibr">64</xref>&#8211;<xref rid="B67" ref-type="bibr">67</xref>). <bold><underline>However, we suggest continuous monitoring of vital signs in association with EEG, since this allows better characterization of seizures and differentiation from non-epileptic paroxysmal events. Also, it permits prompt identification of any possible side effects that could arise during ketamine infusion</underline></bold>(<xref rid="B45" ref-type="bibr">45</xref>)<bold><underline>.</underline></bold></p><p>At 3&#8211;17&#8197;months, it was reported good seizure control in 80% of the surviving patients; however, they presented with predominantly motor sequelae (such as hypotonia or spasticity) (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B36" ref-type="bibr">36</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>). There is no consensus over the long-term consequences of ketamine administration in neonates. Studies on adults have shown that prolonged ketamine use may lead to neuropsychiatric impairment, urologic or hepato-biliary injury (<xref rid="B68" ref-type="bibr">68</xref>&#8211;<xref rid="B70" ref-type="bibr">70</xref>). Ketamine is metabolized in the liver by the CYP3A4 system, then excreted through the kidneys and, to a lesser extent, the biliary system. Involvement of both the urinary and biliary tracts suggests that ketamine or its metabolite (norketamine) may have direct toxic effect on the urinary/biliary tract epithelium (<xref rid="B71" ref-type="bibr">71</xref>). Following ketamine administration in rats and nonhuman primates, upregulation of NMDARs has been observed, which after its dismissal would lead to neuronal degeneration and apoptosis (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B72" ref-type="bibr">72</xref>&#8211;<xref rid="B75" ref-type="bibr">75</xref>).</p><p>Mortality rate in neonatal SE is reported to be around 9%&#8211;24% (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). In our review the overall mortality rate was 37.5%. This higher rate may be related to the small sample size of our cohort, but also to the severity of the underlying pathology of the neonates affected, as in our case report.</p><p>Limitations to this study included the very small population and the heterogeneity of data collected from the selected articles, which did not allow to perform a metanalysis. In some cases, it was not possible to ascertain the raw data.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>To the best of our knowledge this is the first systematic review on the use of ketamine for the treatment of neonatal SE. <underline><bold>Evidence suggests that ketamine could be used as third line treatment, due to its pharmacodynamic, different from the most used GABA-ergic ASM.</bold></underline></p><p>Despite the above-mentioned limitations, ketamine showed a promising efficacy and safety profile. Rationale for its use in this setting finds confirmation both in pharmacodynamics mechanisms and in the peculiar anatomic-functional characteristics of neonatal brain. Given the pathophysiology of the immature brain, its efficacy could be even higher in newborns, highlighting its possible role in terms of precision medicine for the treatment of neonatal SE. However, our study is limited by a knowledge gap in the long-term outcomes of ketamine administration in neonates, that yet needs to be properly assessed in randomized clinical trials and larger studies.</p></sec></body><back><sec sec-type="author-contributions" id="s6"><title>Author contributions</title><p>LL and JNP carried out the literature review and drafted the paper. MN and MEC contributed to the last version of the manuscript. EB and SS provided senior support for the article conceptualization and contributed to the last version of the manuscript. CG, AZ, GP, AR, IT: supervised the literature review and contributed to the critical revision of the manuscript. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="s7"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s9"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s8"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fped.2023.1189478/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fped.2023.1189478/full#supplementary-material</ext-link></p><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table1.docx" id="d95e1319" position="anchor" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trinka</surname><given-names>E</given-names></name><name name-style="western"><surname>Cock</surname><given-names>H</given-names></name><name name-style="western"><surname>Hesdorffer</surname><given-names>D</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>AO</given-names></name><name name-style="western"><surname>Scheffer</surname><given-names>IE</given-names></name><name name-style="western"><surname>Shinnar</surname><given-names>S</given-names></name><etal/></person-group><article-title>A definition and classification of status epilepticus&#8211;report of the ILAE task force on classification of Status epilepticus</article-title>. <source>Epilepsia</source>. (<year>2015</year>) <volume>56</volume>(<issue>10</issue>):<fpage>1515</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1111/epi13121</pub-id><pub-id pub-id-type="pmid">26336950</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsch</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Gaspard</surname><given-names>N</given-names></name><name name-style="western"><surname>van Baalen</surname><given-names>A</given-names></name><name name-style="western"><surname>Nabbout</surname><given-names>R</given-names></name><name name-style="western"><surname>Demeret</surname><given-names>S</given-names></name><name name-style="western"><surname>Loddenkemper</surname><given-names>T</given-names></name><etal/></person-group><article-title>Proposed consensus definitions for new-onset refractory Status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions</article-title>. <source>Epilepsia</source>. (<year>2018</year>) <volume>59</volume>(<issue>4</issue>):<fpage>739</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1111/epi.14016</pub-id><pub-id pub-id-type="pmid">29399791</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pressler</surname><given-names>RM</given-names></name><name name-style="western"><surname>Cilio</surname><given-names>MR</given-names></name><name name-style="western"><surname>Mizrahi</surname><given-names>EM</given-names></name><name name-style="western"><surname>Mosh&#233;</surname><given-names>SL</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>ML</given-names></name><name name-style="western"><surname>Plouin</surname><given-names>P</given-names></name><etal/></person-group><article-title>The ILAE classification of seizures and the epilepsies: modification for seizures in the neonate. Position paper by the ILAE task force on neonatal seizures</article-title>. <source>Epilepsia</source>. (<year>2021</year>) <volume>62</volume>(<issue>3</issue>):<fpage>615</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1111/epi.16815</pub-id><pub-id pub-id-type="pmid">33522601</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abend</surname><given-names>NS</given-names></name><name name-style="western"><surname>Wusthoff</surname><given-names>CJ</given-names></name></person-group>. <article-title>Neonatal seizures and status epilepticus</article-title>. <source>J Clin Neurophysiol</source>. (<year>2012</year>) <volume>29</volume>(<issue>5</issue>):<fpage>441</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/WNP.0b013e31826bd90d</pub-id><pub-id pub-id-type="pmid">23027101</pub-id><pub-id pub-id-type="pmcid">PMC3463810</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ziobro</surname><given-names>JM</given-names></name><name name-style="western"><surname>Eschbach</surname><given-names>K</given-names></name><name name-style="western"><surname>Shellhaas</surname><given-names>RA</given-names></name></person-group><article-title>Novel therapeutics for neonatal seizures</article-title>. <source>Neurotherapeutics</source> (<year>2021</year>) <volume>18</volume>(<issue>3</issue>):<fpage>1564</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-021-01085-8</pub-id><pub-id pub-id-type="pmid">34386906</pub-id><pub-id pub-id-type="pmcid">PMC8608938</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padiyar</surname><given-names>S</given-names></name><name name-style="western"><surname>Nusairat</surname><given-names>L</given-names></name><name name-style="western"><surname>Kadri</surname><given-names>A</given-names></name><name name-style="western"><surname>Abu-Shaweesh</surname><given-names>J</given-names></name><name name-style="western"><surname>Aly</surname><given-names>H</given-names></name></person-group>. <article-title>Neonatal seizures in the U.S. National inpatient population: prevalence and outcomes</article-title>. <source>Pediatr Neonatol</source>. (<year>2020</year>) <volume>61</volume>(<issue>3</issue>):<fpage>300</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.pedneo.2019.12.006</pub-id><pub-id pub-id-type="pmid">31937508</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baudou</surname><given-names>E</given-names></name><name name-style="western"><surname>Cances</surname><given-names>C</given-names></name><name name-style="western"><surname>Dimeglio</surname><given-names>C</given-names></name><name name-style="western"><surname>Hachon Lecamus</surname><given-names>C</given-names></name></person-group>. <article-title>Etiology of neonatal seizures and maintenance therapy use: a 10-year retrospective study at Toulouse children&#8217;s hospital</article-title>. <source>BMC Pediatr</source>. (<year>2019</year>) <volume>19</volume>(<issue>1</issue>):<fpage>136</fpage>. <pub-id pub-id-type="doi">10.1186/s12887-019-1508-5</pub-id><pub-id pub-id-type="pmid">31035972</pub-id><pub-id pub-id-type="pmcid">PMC6487521</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wertheim</surname><given-names>D</given-names></name><name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></name><name name-style="western"><surname>Faundez</surname><given-names>JC</given-names></name><name name-style="western"><surname>Rutherford</surname><given-names>M</given-names></name><name name-style="western"><surname>Acolet</surname><given-names>D</given-names></name><name name-style="western"><surname>Dubowitz</surname><given-names>L</given-names></name></person-group>. <article-title>Prognostic value of continuous electroencephalographic recording in full term infants with hypoxic ischaemic encephalopathy</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source>. (<year>1994</year>) <volume>71</volume>(<issue>2</issue>):<fpage>F97</fpage>&#8211;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1136/fn.71.2.f97</pub-id><pub-id pub-id-type="pmid">7979486</pub-id><pub-id pub-id-type="pmcid">PMC1061091</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McBride</surname><given-names>MC</given-names></name><name name-style="western"><surname>Laroia</surname><given-names>N</given-names></name><name name-style="western"><surname>Guillet</surname><given-names>R</given-names></name></person-group>. <article-title>Electrographic seizures in neonates correlate with poor neurodevelopmental outcome</article-title>. <source>Neurology</source>. (<year>2000</year>) <volume>55</volume>(<issue>4</issue>):<fpage>506</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.55.4.506</pub-id><pub-id pub-id-type="pmid">10953181</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavlidis</surname><given-names>E</given-names></name><name name-style="western"><surname>Spagnoli</surname><given-names>C</given-names></name><name name-style="western"><surname>Pelosi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mazzotta</surname><given-names>S</given-names></name><name name-style="western"><surname>Pisani</surname><given-names>F</given-names></name></person-group>. <article-title>Neonatal Status epilepticus: differences between preterm and term newborns</article-title>. <source>Eur J Paediatr Neurol</source>. (<year>2015</year>) <volume>19</volume>(<issue>3</issue>):<fpage>314</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpn.2015.01.002</pub-id><pub-id pub-id-type="pmid">25613545</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahrens</surname><given-names>S</given-names></name><name name-style="western"><surname>Ream</surname><given-names>MA</given-names></name><name name-style="western"><surname>Slaughter</surname><given-names>LA</given-names></name></person-group>. <article-title>Status epilepticus in the neonate: updates in treatment strategies</article-title>. <source>Curr Treat Options Neurol</source>. (<year>2019</year>) <volume>21</volume>(<issue>2</issue>):<fpage>8</fpage>. <pub-id pub-id-type="doi">10.1007/s11940-019-0546-5</pub-id><pub-id pub-id-type="pmid">30773607</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Heuser</surname><given-names>K</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>KB</given-names></name><name name-style="western"><surname>Ulvin</surname><given-names>LB</given-names></name><name name-style="western"><surname>Gjerstad</surname><given-names>L</given-names></name><name name-style="western"><surname>Taubol</surname><given-names>E</given-names></name></person-group>. <article-title>Modern treatment of status epilepticus in adults</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Czuczwar</surname><given-names>SJ</given-names></name></person-group>, editors. <source>Epilepsy</source>. <publisher-loc>Brisbane</publisher-loc>, <publisher-loc>AU</publisher-loc>: <publisher-name>Exon Publications</publisher-name> (<year>2022</year>).<pub-id pub-id-type="pmid">35605086</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaspard</surname><given-names>N</given-names></name><name name-style="western"><surname>Foreman</surname><given-names>BP</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>V</given-names></name><name name-style="western"><surname>Cabrera Kang</surname><given-names>C</given-names></name><name name-style="western"><surname>Probasco</surname><given-names>JC</given-names></name><name name-style="western"><surname>Jongeling</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Critical care EEG monitoring research Consortium (CCEMRC). New-onset refractory status epilepticus: etiology, clinical features, and outcome</article-title>. <source>Neurology</source>. (<year>2015</year>) <volume>85</volume>(<issue>18</issue>):<fpage>1604</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000001940</pub-id><pub-id pub-id-type="pmid">26296517</pub-id><pub-id pub-id-type="pmcid">PMC4642147</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alkhachroum</surname><given-names>A</given-names></name><name name-style="western"><surname>Der-Nigoghossian</surname><given-names>CA</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>E</given-names></name><name name-style="western"><surname>Massad</surname><given-names>N</given-names></name><name name-style="western"><surname>Letchinger</surname><given-names>R</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>K</given-names></name><etal/></person-group><article-title>Ketamine to treat super-refractory status epilepticus</article-title>. <source>Neurology</source>. (<year>2020</year>) <volume>95</volume>(<issue>16</issue>):<fpage>e2286</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000010611</pub-id><pub-id pub-id-type="pmid">32873691</pub-id><pub-id pub-id-type="pmcid">PMC7713785</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagae</surname><given-names>L</given-names></name></person-group>. <article-title>Paediatric Status epilepticus: finally, some evidence-based treatment guidance, but still a long way to go</article-title>. <source>Lancet Child Adolesc Health</source>. (<year>2020</year>) <volume>4</volume>(<issue>5</issue>):<fpage>351</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-4642(20)30030-4</pub-id><pub-id pub-id-type="pmid">32336347</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>M</given-names></name><name name-style="western"><surname>Fox</surname><given-names>SM</given-names></name></person-group>. <article-title>Pediatric seizures</article-title>. <source>Emerg Med Clin North Am</source>. (<year>2013</year>) <volume>31</volume>(<issue>3</issue>):<fpage>733</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.emc.2013.04.001</pub-id><pub-id pub-id-type="pmid">23915601</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swarnalingam</surname><given-names>E</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>K</given-names></name><name name-style="western"><surname>Esser</surname><given-names>M</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>J</given-names></name></person-group>. <article-title>Management and prognosis of pediatric status epilepticus</article-title>. <source>Z. Epileptol</source><italic toggle="yes">.</italic> (<year>2022</year>) <volume>35</volume>(<issue>4</issue>):<fpage>332</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1007/s10309-022-00538-0</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Van Hove</surname><given-names>JLK</given-names></name><name name-style="western"><surname>Coughlin</surname><given-names>C II</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>M</given-names></name><name name-style="western"><surname>Hennermann</surname><given-names>JB</given-names></name></person-group>. <article-title>Nonketotic hyperglycinemia</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>MP</given-names></name><name name-style="western"><surname>Everman</surname><given-names>DB</given-names></name><name name-style="western"><surname>Mirzaa</surname><given-names>GM</given-names></name><name name-style="western"><surname>Pagon</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>SE</given-names></name><name name-style="western"><surname>Bean</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Gripp</surname><given-names>KW</given-names></name><name name-style="western"><surname>Amemiya</surname><given-names>A</given-names></name></person-group>, editors. <source>Genereviews&#174;</source>. <publisher-loc>Seattle</publisher-loc>, <publisher-loc>WA</publisher-loc>: <publisher-name>University of Washington</publisher-name> (<year>1993</year>).<pub-id pub-id-type="pmid">20301531</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keros</surname><given-names>S</given-names></name><name name-style="western"><surname>Buraniqi</surname><given-names>E</given-names></name><name name-style="western"><surname>Alex</surname><given-names>B</given-names></name><name name-style="western"><surname>Antonetty</surname><given-names>A</given-names></name><name name-style="western"><surname>Fialho</surname><given-names>H</given-names></name><name name-style="western"><surname>Hafeez</surname><given-names>B</given-names></name><etal/></person-group><article-title>Increasing ketamine use for refractory status epilepticus in US pediatric hospitals</article-title>. <source>J Child Neurol</source>. (<year>2017</year>) <volume>32</volume>(<issue>7</issue>):<fpage>638</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1177/0883073817698629</pub-id><pub-id pub-id-type="pmid">28349774</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korman</surname><given-names>SH</given-names></name><name name-style="western"><surname>Wexler</surname><given-names>ID</given-names></name><name name-style="western"><surname>Gutman</surname><given-names>A</given-names></name><name name-style="western"><surname>Rolland</surname><given-names>MO</given-names></name><name name-style="western"><surname>Kanno</surname><given-names>J</given-names></name><name name-style="western"><surname>Kure</surname><given-names>S</given-names></name></person-group>. <article-title>Treatment from birth of nonketotic hyperglycinemia due to a novel GLDC mutation</article-title>. <source>Ann Neurol</source><year>2006</year>, <volume>59</volume> (<issue>2</issue>), <fpage>411</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/ana.20759</pub-id><pub-id pub-id-type="pmid">16404748</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rostaminejad</surname><given-names>M</given-names></name><name name-style="western"><surname>Rostaminejad</surname><given-names>A</given-names></name></person-group>. <article-title>Treatment of refractory status epilepticus with intravenous anesthetic agents: a systematic review</article-title>. <source>Trends Anaesth Crit Care</source>. (<year>2022</year>) <volume>44</volume>:<fpage>8</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.tacc.2022.04.003</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobwitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Mulvihill</surname><given-names>C</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>MC</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>AK</given-names></name><name name-style="western"><surname>Resendiz</surname><given-names>K</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Ketamine for management of neonatal and pediatric refractory status epilepticus</article-title>. <source>Neurology</source>. (<year>2022</year>) <volume>99</volume>(<issue>12</issue>):<fpage>e1227</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000200889</pub-id><pub-id pub-id-type="pmid">35817569</pub-id><pub-id pub-id-type="pmcid">PMC10499431</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>S</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>I</given-names></name><name name-style="western"><surname>Bastrenta</surname><given-names>P</given-names></name><name name-style="western"><surname>Mastrangelo</surname><given-names>M</given-names></name><name name-style="western"><surname>Lista</surname><given-names>G</given-names></name></person-group>. <article-title>Early myoclonic encephalopathy and nonketotic hyperglycinemia</article-title>. <source>Pediatr Neurol</source>. (<year>2009</year>) <volume>41</volume>(<issue>5</issue>):<fpage>371</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2009.05.005</pub-id><pub-id pub-id-type="pmid">19818941</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khraim</surname><given-names>W</given-names></name><name name-style="western"><surname>Abu-Libdeh</surname><given-names>B</given-names></name><name name-style="western"><surname>Ayesh</surname><given-names>S</given-names></name><name name-style="western"><surname>Dweikat</surname><given-names>I</given-names></name></person-group>. <article-title>Clinical heterogeneity of glycine encephalopathy in three palestinian siblings: a novel mutation in the glycine decarboxylase (GLDC) gene</article-title>. <source>Brain Dev</source>. (<year>2017</year>) <volume>39</volume>(<issue>7</issue>):<fpage>601</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2017.03.005</pub-id><pub-id pub-id-type="pmid">28325525</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poothrikovil</surname><given-names>RP</given-names></name><name name-style="western"><surname>Al Thihli</surname><given-names>K</given-names></name><name name-style="western"><surname>Al Futaisi</surname><given-names>A</given-names></name><name name-style="western"><surname>Al Murshidi</surname><given-names>F</given-names></name></person-group>. <article-title>Nonketotic hyperglycinemia: two case reports and review</article-title>. <source>Neurodiagn J</source>. (<year>2019</year>) <volume>59</volume>(<issue>3</issue>):<fpage>142</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1080/21646821.2019.1645549</pub-id><pub-id pub-id-type="pmid">31433733</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demirel</surname><given-names>N</given-names></name><name name-style="western"><surname>Bas</surname><given-names>AY</given-names></name><name name-style="western"><surname>Zenciroglu</surname><given-names>A</given-names></name><name name-style="western"><surname>Aydemir</surname><given-names>C</given-names></name><name name-style="western"><surname>Kalkanoglu</surname><given-names>S</given-names></name><name name-style="western"><surname>Coskun</surname><given-names>T</given-names></name></person-group>. <article-title>Neonatal non-ketotic hyperglycinemia: report of five cases</article-title>. <source>Pediatr Int</source>. (<year>2008</year>) <volume>50</volume>(<issue>1</issue>):<fpage>121</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1111/j.1442-200X.2007.02513.x</pub-id><pub-id pub-id-type="pmid">18279221</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kure</surname><given-names>S</given-names></name><name name-style="western"><surname>Oota</surname><given-names>M</given-names></name><name name-style="western"><surname>Hino</surname><given-names>H</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>M</given-names></name></person-group>. <article-title>Nonketotic hyperglycinemia: proposal of a diagnostic and treatment strategy</article-title>. <source>Pediatr Neurol</source>. (<year>2010</year>) <volume>43</volume>(<issue>3</issue>):<fpage>221</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2010.04.018</pub-id><pub-id pub-id-type="pmid">20691948</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atay</surname><given-names>E</given-names></name><name name-style="western"><surname>Bozaykut</surname><given-names>A</given-names></name><name name-style="western"><surname>Sezer</surname><given-names>G</given-names></name></person-group>. <article-title>Four cases of neonatal non-ketotic hyperglycinaemia</article-title>. <source>Ann Trop Paediatr</source>. (<year>2004</year>) <volume>24</volume>(<issue>4</issue>):<fpage>345</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1179/027249304225019172</pub-id><pub-id pub-id-type="pmid">15720892</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosati</surname><given-names>A</given-names></name><name name-style="western"><surname>Ilvento</surname><given-names>L</given-names></name><name name-style="western"><surname>L'Erario</surname><given-names>M</given-names></name><name name-style="western"><surname>De Masi</surname><given-names>S</given-names></name><name name-style="western"><surname>Biggeri</surname><given-names>A</given-names></name><name name-style="western"><surname>Fabbro</surname><given-names>G</given-names></name><etal/></person-group><article-title>Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01)</article-title>. <source>BMJ Open</source>. (<year>2016</year>) <volume>6</volume>(<issue>6</issue>):<fpage>e011565</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2016-011565</pub-id><pub-id pub-id-type="pmid">27311915</pub-id><pub-id pub-id-type="pmcid">PMC4916612</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samanta</surname><given-names>D</given-names></name></person-group>. <article-title>Ketamine in refractory neonatal seizures</article-title>. <source>Pediatr Neurol</source>. (<year>2020</year>) <volume>106</volume>:<fpage>76</fpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2019.11.012</pub-id><pub-id pub-id-type="pmid">31917102</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huntsman</surname><given-names>RJ</given-names></name></person-group>. <article-title>Response to samanta &#8220;are ketamine infusions a viable therapeutic option for refractory neonatal seizures?&#8221;</article-title>. <source>Pediatr Neurol</source><year>2020</year>;<volume>106</volume>:<fpage>76</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2020.02.001</pub-id><pub-id pub-id-type="pmid">32173160</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandal</surname><given-names>V</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>A</given-names></name><name name-style="western"><surname>Tirol</surname><given-names>F</given-names></name><name name-style="western"><surname>Kaushal</surname><given-names>S</given-names></name><name name-style="western"><surname>Pergami</surname><given-names>P</given-names></name></person-group>. <article-title>2022 Eastern regional meeting</article-title>. <source>J Invest Med</source>. (<year>2022</year>) <volume>70</volume>(<issue>4</issue>):<fpage>977</fpage>&#8211;<lpage>1202</lpage>. <pub-id pub-id-type="doi">10.1136/jim-2022-ERM</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huntsman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Strueby</surname><given-names>L</given-names></name><name name-style="western"><surname>Bingham</surname><given-names>W</given-names></name></person-group>. <article-title>Are ketamine infusions a viable therapeutic option for refractory neonatal seizures?</article-title><source>Pediatr Neurol</source>. (<year>2020</year>) <volume>103</volume>:<fpage>8</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2019.09.003</pub-id><pub-id pub-id-type="pmid">31601453</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freibauer</surname><given-names>A</given-names></name><name name-style="western"><surname>Jones</surname><given-names>K</given-names></name></person-group>. <article-title>KCNQ2 mutation in an infant with encephalopathy of infancy with migrating focal seizures</article-title>. <source>Epileptic Disord</source>. (<year>2018</year>) <volume>20</volume>(<issue>6</issue>):<fpage>541</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1684/epd.2018.1011</pub-id><pub-id pub-id-type="pmid">30530441</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarocco</surname><given-names>A</given-names></name><name name-style="western"><surname>Ballardini</surname><given-names>E</given-names></name><name name-style="western"><surname>Garani</surname><given-names>G</given-names></name></person-group>. <article-title>Use of ketamine in a newborn with refractory status epilepticus: a case report</article-title>. <source>Pediatr Neurol</source>. (<year>2014</year>) <volume>51</volume>(<issue>1</issue>):<fpage>154</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2014.03.006</pub-id><pub-id pub-id-type="pmid">24938144</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhamija</surname><given-names>R</given-names></name><name name-style="western"><surname>Mack</surname><given-names>KJ</given-names></name></person-group>. <article-title>A 2-day-old baby girl with encephalopathy and burst suppression on EEG. Nonketotic hyperglycinemia</article-title>. <source>Neurology</source><year>2011</year>, <volume>77</volume> (<issue>3</issue>), <fpage>e16</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e318225aae3</pub-id><pub-id pub-id-type="pmid">21768594</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haider</surname><given-names>N</given-names></name><name name-style="western"><surname>Salih</surname><given-names>MA</given-names></name><name name-style="western"><surname>Al-Rasheed</surname><given-names>S</given-names></name><name name-style="western"><surname>Al-Mofada</surname><given-names>S</given-names></name><name name-style="western"><surname>Krahn</surname><given-names>PM</given-names></name><name name-style="western"><surname>Kabiraj</surname><given-names>M</given-names></name></person-group>. <article-title>Nonketotic hyperglycinemia: a life-threatening disorder in Saudi newborns</article-title>. <source>Ann Saudi Med</source>. (<year>1996</year>) <volume>16</volume>(<issue>4</issue>):<fpage>400</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.5144/0256-4947.1996.400</pub-id><pub-id pub-id-type="pmid">17372475</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tegtmeyer-Metzdorf</surname><given-names>H</given-names></name><name name-style="western"><surname>Roth</surname><given-names>B</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>M</given-names></name><name name-style="western"><surname>Theisohn</surname><given-names>M</given-names></name><name name-style="western"><surname>Heinemann</surname><given-names>U</given-names></name><name name-style="western"><surname>Adams</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Ketamine and strychnine treatment of an infant with nonketotic hyperglycinaemia</article-title>. <source>Eur J Pediatr</source>. (<year>1995</year>) <volume>154</volume>(<issue>8</issue>):<fpage>649</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/BF02079070</pub-id><pub-id pub-id-type="pmid">7588967</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>HC</given-names></name><name name-style="western"><surname>Shellhaas</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wusthoff</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Chang</surname><given-names>T</given-names></name><name name-style="western"><surname>Abend</surname><given-names>NS</given-names></name><name name-style="western"><surname>Chu</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Neonatal seizure registry study group. Contemporary profile of seizures in neonates: a prospective cohort study</article-title>. <source>J Pediatr</source>. (<year>2016</year>) <volume>174</volume>:<fpage>98</fpage>&#8211;<lpage>103.e1</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2016.03.035</pub-id><pub-id pub-id-type="pmid">27106855</pub-id><pub-id pub-id-type="pmcid">PMC4925241</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douglas-Escobar</surname><given-names>M</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>MD</given-names></name></person-group>. <article-title>Hypoxic-ischemic encephalopathy: a review for the clinician</article-title>. <source>JAMA Pediatr</source>. (<year>2015</year>) <volume>169</volume>(<issue>4</issue>):<fpage>397</fpage>&#8211;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1001/jamapediatrics.2014</pub-id><pub-id pub-id-type="pmid">25685948</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pellegrin</surname><given-names>S</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>FM</given-names></name><name name-style="western"><surname>Padula</surname><given-names>M</given-names></name><name name-style="western"><surname>Heath</surname><given-names>PT</given-names></name><name name-style="western"><surname>Meller</surname><given-names>L</given-names></name><name name-style="western"><surname>Top</surname><given-names>K</given-names></name><etal/></person-group><article-title>Brighton collaboration neonatal seizures working group. Neonatal seizures: case definition &amp; guidelines for data collection, analysis, and presentation of immunization safety data</article-title>. <source>Vaccine</source>. (<year>2019</year>) <volume>37</volume>(<issue>52</issue>):<fpage>7596</fpage>&#8211;<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2019.05.031</pub-id><pub-id pub-id-type="pmid">31783981</pub-id><pub-id pub-id-type="pmcid">PMC6899436</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shellhaas</surname><given-names>RA</given-names></name><name name-style="western"><surname>Chang</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsuchida</surname><given-names>T</given-names></name><name name-style="western"><surname>Scher</surname><given-names>MS</given-names></name><name name-style="western"><surname>Riviello</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Abend</surname><given-names>NS</given-names></name><etal/></person-group><article-title>The American clinical neurophysiology society&#8217;s guideline on continuous electroencephalography monitoring in neonates</article-title>. <source>J Clin Neurophysiol</source>. (<year>2011</year>) <volume>28</volume>(<issue>6</issue>):<fpage>611</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/WNP.0b013e31823e96d7</pub-id><pub-id pub-id-type="pmid">22146359</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanker</surname><given-names>A</given-names></name><name name-style="western"><surname>Abel</surname><given-names>JH</given-names></name><name name-style="western"><surname>Schamberg</surname><given-names>G</given-names></name><name name-style="western"><surname>Brown</surname><given-names>EN</given-names></name></person-group>. <article-title>Etiology of burst suppression EEG patterns</article-title>. <source>Front Psychol</source>. (<year>2021</year>) <volume>12</volume>:<fpage>673529</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyg.2021.673529</pub-id><pub-id pub-id-type="pmid">34177731</pub-id><pub-id pub-id-type="pmcid">PMC8222661</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>ML</given-names></name><name name-style="western"><surname>Malloy</surname><given-names>KM</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>SN</given-names></name><name name-style="western"><surname>Rose</surname><given-names>RS</given-names></name><name name-style="western"><surname>Buss</surname><given-names>WF</given-names></name><name name-style="western"><surname>Mietzsch</surname><given-names>U</given-names></name></person-group>. <article-title>Standardized treatment of neonatal status epilepticus improves outcome</article-title>. <source>J Child Neurol</source>. (<year>2016</year>) <volume>31</volume>(<issue>14</issue>):<fpage>1546</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1177/0883073816664670</pub-id><pub-id pub-id-type="pmid">27581850</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharpe</surname><given-names>C</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>GE</given-names></name><name name-style="western"><surname>Davis</surname><given-names>SL</given-names></name><name name-style="western"><surname>Nespeca</surname><given-names>M</given-names></name><name name-style="western"><surname>Gold</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial</article-title>. <source>Pediatrics</source>. (<year>2020</year>) <volume>145</volume>(<issue>6</issue>):<fpage>e20193182</fpage>. <pub-id pub-id-type="doi">10.1542/peds.2019-3182</pub-id><pub-id pub-id-type="pmid">32385134</pub-id><pub-id pub-id-type="pmcid">PMC7263056</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>HC</given-names></name><name name-style="western"><surname>Kan</surname><given-names>J</given-names></name><name name-style="western"><surname>Bonifacio</surname><given-names>SL</given-names></name><name name-style="western"><surname>Ferriero</surname><given-names>DM</given-names></name></person-group>. <article-title>Neonatal seizures: treatment practices among term and preterm infants</article-title>. <source>Pediatr Neurol</source>. (<year>2012</year>) <volume>46</volume>(<issue>2</issue>):<fpage>111</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2011.11.006</pub-id><pub-id pub-id-type="pmid">22264706</pub-id><pub-id pub-id-type="pmcid">PMC3266555</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chien</surname><given-names>YH</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A</given-names></name><name name-style="western"><surname>Chou</surname><given-names>SP</given-names></name><name name-style="western"><surname>Lu</surname><given-names>FL</given-names></name><name name-style="western"><surname>Lee</surname><given-names>WT</given-names></name><etal/></person-group><article-title>Poor outcome for neonatal-type nonketotic hyperglycinemia treated with high-dose sodium benzoate and dextromethorphan</article-title>. <source>J Child Neurol</source>. (<year>2004</year>) <volume>19</volume>(<issue>1</issue>):<fpage>39</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1177/08830738040190010702</pub-id><pub-id pub-id-type="pmid">15032382</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mastrangelo</surname><given-names>M</given-names></name><name name-style="western"><surname>Canafoglia</surname><given-names>L</given-names></name><name name-style="western"><surname>Franceschetti</surname><given-names>S</given-names></name><name name-style="western"><surname>Oppezzo</surname><given-names>C</given-names></name><name name-style="western"><surname>Mosca</surname><given-names>F</given-names></name><name name-style="western"><surname>Menni</surname><given-names>F</given-names></name><etal/></person-group><article-title>High-frequency rhythmic cortical myoclonus in a long-surviving patient with nonketotic hypergylcemia</article-title>. <source>J Child Neurol</source>. (<year>2008</year>) <volume>23</volume>(<issue>3</issue>):<fpage>321</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1177/0883073807308699</pub-id><pub-id pub-id-type="pmid">18182648</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>J</given-names></name><name name-style="western"><surname>Okabe</surname><given-names>A</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>H</given-names></name><name name-style="western"><surname>Kilb</surname><given-names>W</given-names></name><name name-style="western"><surname>Luhmann</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>A</given-names></name></person-group>. <article-title>Cl- uptake promoting depolarizing GABA actions in immature rat neocortical neurones is mediated by NKCC1</article-title>. <source>J Physiol</source>. (<year>2004</year>) <volume>557</volume>(<issue>Pt 3</issue>):<fpage>829</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2004.062471</pub-id><pub-id pub-id-type="pmid">15090604</pub-id><pub-id pub-id-type="pmcid">PMC1665166</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>FE</given-names></name></person-group>. <article-title>Developmental factors in the pathogenesis of neonatal seizures</article-title>. <source>J Pediatr Neurol</source>. (<year>2009</year>) <volume>7</volume>(<issue>1</issue>):<fpage>5</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.3233/JPN-2009-0270</pub-id><pub-id pub-id-type="pmid">20191097</pub-id><pub-id pub-id-type="pmcid">PMC2828632</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodkin</surname><given-names>HP</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kapur</surname><given-names>J</given-names></name></person-group>. <article-title>Status epilepticus increases the intracellular accumulation of GABAA receptors</article-title>. <source>J. Neurosci</source><italic toggle="yes">.</italic><year>2005</year>, <volume>25</volume> (<issue>23</issue>), <fpage>5511</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0900-05.2005</pub-id><pub-id pub-id-type="pmid">15944379</pub-id><pub-id pub-id-type="pmcid">PMC2878479</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Abend</surname><given-names>NS</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>FE</given-names></name><name name-style="western"><surname>Inder</surname><given-names>TE</given-names></name><name name-style="western"><surname>Volpe</surname><given-names>JJ</given-names></name></person-group>. <article-title>Chapter 12&#8212;neonatal seizures</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Volpe</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Inder</surname><given-names>TE</given-names></name><etal/></person-group>, editors. <source>Volpe&#8217;s neurology of the newborn (Sixth edn)</source>. <publisher-name>Elsevier</publisher-name> (<year>2018</year>). p. <fpage>275</fpage>&#8211;<lpage>321.e14</lpage>. <comment>doi: 10.1016/B978-0-323-42876-7.00012-0</comment>.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez</surname><given-names>RM</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>FE</given-names></name></person-group>. <article-title>Maturational aspects of epilepsy mechanisms and consequences for the immature brain</article-title>. <source>Epilepsia</source>. (<year>2001</year>) <volume>42</volume>(<issue>5</issue>):<fpage>577</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1046/j.1528-1157.2001.12000.x</pub-id><pub-id pub-id-type="pmid">11380563</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Klein</surname><given-names>PM</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>FE</given-names></name></person-group>. <article-title>Neonatal seizures Alter NMDA glutamate receptor GluN2A and 3A subunit expression and function in hippocampal CA1 neurons</article-title>. <source>Front Cell Neurosci</source>. (<year>2015</year>) <volume>9</volume>. <pub-id pub-id-type="doi">10.3389/fncel.2015.00362</pub-id><pub-id pub-id-type="pmcid">PMC4585040</pub-id><pub-id pub-id-type="pmid">26441533</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dingledine</surname><given-names>R</given-names></name><name name-style="western"><surname>Borges</surname><given-names>K</given-names></name><name name-style="western"><surname>Bowie</surname><given-names>D</given-names></name><name name-style="western"><surname>Traynelis</surname><given-names>SF</given-names></name></person-group>. <article-title>The glutamate receptor Ion channels</article-title>. <source>Pharmacol Rev</source>. (<year>1999</year>) <volume>51</volume>(<issue>1</issue>):<fpage>7</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">10049997</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henschel</surname><given-names>O</given-names></name><name name-style="western"><surname>Gipson</surname><given-names>KE</given-names></name><name name-style="western"><surname>Bordey</surname><given-names>A</given-names></name></person-group>. <article-title>GABAA Receptors, anesthetics and anticonvulsants in brain development</article-title>. <source>CNS Neurol Disord Drug Targets</source>. (<year>2008</year>) <volume>7</volume>(<issue>2</issue>):<fpage>211</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.2174/187152708784083812</pub-id><pub-id pub-id-type="pmid">18537647</pub-id><pub-id pub-id-type="pmcid">PMC2557552</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leinekugel</surname><given-names>X</given-names></name><name name-style="western"><surname>Khalilov</surname><given-names>I</given-names></name><name name-style="western"><surname>McLean</surname><given-names>H</given-names></name><name name-style="western"><surname>Caillard</surname><given-names>O</given-names></name><name name-style="western"><surname>Gaiarsa</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ben-Ari</surname><given-names>Y</given-names></name><etal/></person-group><article-title>GABA Is the principal fast-acting excitatory transmitter in the neonatal brain</article-title>. <source>Adv Neurol</source>. (<year>1999</year>) <volume>79</volume>:<fpage>189</fpage>&#8211;<lpage>201</lpage>.<pub-id pub-id-type="pmid">10514814</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owens</surname><given-names>DF</given-names></name><name name-style="western"><surname>Boyce</surname><given-names>LH</given-names></name><name name-style="western"><surname>Davis</surname><given-names>MB</given-names></name><name name-style="western"><surname>Kriegstein</surname><given-names>AR</given-names></name></person-group>. <article-title>Excitatory GABA responses in embryonic and neonatal cortical slices demonstrated by gramicidin perforated-patch recordings and calcium imaging</article-title>. <source>J Neurosci</source>. (<year>1996</year>) <volume>16</volume>(<issue>20</issue>):<fpage>6414</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.16-20-06414.1996</pub-id><pub-id pub-id-type="pmid">8815920</pub-id><pub-id pub-id-type="pmcid">PMC6578913</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rakhade</surname><given-names>SN</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>FE</given-names></name></person-group>. <article-title>Epileptogenesis in the immature brain: emerging mechanisms</article-title>. <source>Nat Rev Neurol</source>. (<year>2009</year>) <volume>5</volume>(<issue>7</issue>):<fpage>380</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2009.80</pub-id><pub-id pub-id-type="pmid">19578345</pub-id><pub-id pub-id-type="pmcid">PMC2822660</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Rosch</surname><given-names>RE</given-names></name><name name-style="western"><surname>Wilmshurst</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sen</surname><given-names>A</given-names></name><name name-style="western"><surname>Ramantani</surname><given-names>G</given-names></name><name name-style="western"><surname>Akerman</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Why won&#8217;t it stop? The dynamics of benzodiazepine resistance in Status epilepticus</article-title>. <source>Nat Rev Neurol</source>. (<year>2022</year>) <volume>18</volume>(<issue>7</issue>):<fpage>428</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1038/s41582-022-00664-3</pub-id><pub-id pub-id-type="pmid">35538233</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>HC</given-names></name><name name-style="western"><surname>Shellhaas</surname><given-names>RA</given-names></name></person-group>. <article-title>Acute symptomatic seizures in neonates</article-title>. <source>Semin Pediatr Neurol</source>. (<year>2019</year>) <volume>32</volume>:<fpage>100768</fpage>. <pub-id pub-id-type="doi">10.1016/j.spen.2019.08.004</pub-id><pub-id pub-id-type="pmid">31813514</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raspall-Chaure</surname><given-names>M</given-names></name><name name-style="western"><surname>Chin</surname><given-names>RF</given-names></name><name name-style="western"><surname>Neville</surname><given-names>BG</given-names></name><name name-style="western"><surname>Scott</surname><given-names>RC</given-names></name></person-group>. <article-title>Outcome of paediatric convulsive Status epilepticus: a systematic review</article-title>. <source>The Lancet Neurology</source>. (<year>2006</year>) <volume>5</volume>(<issue>9</issue>):<fpage>769</fpage>&#8211;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(06)70546-4</pub-id><pub-id pub-id-type="pmid">16914405</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>RF</given-names></name><name name-style="western"><surname>Neville</surname><given-names>BG</given-names></name><name name-style="western"><surname>Peckham</surname><given-names>C</given-names></name><name name-style="western"><surname>Bedford</surname><given-names>H</given-names></name><name name-style="western"><surname>Wade</surname><given-names>A</given-names></name><name name-style="western"><surname>Scott</surname><given-names>RC</given-names></name></person-group>. <article-title>NLSTEPSS collaborative group. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study</article-title>. <source>Lancet</source>. (<year>2006</year>) <volume>368</volume>(<issue>9531</issue>):<fpage>222</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(06)69043-0</pub-id><pub-id pub-id-type="pmid">16844492</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craven</surname><given-names>R</given-names></name></person-group>. <article-title>Ketamine</article-title>. <source>Anaesthesia</source>. (<year>2007</year>) <volume>62</volume>(<issue>Suppl 1</issue>):<fpage>48</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2044.2007.05298.x</pub-id><pub-id pub-id-type="pmid">17937714</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griesdale</surname><given-names>DE</given-names></name><name name-style="western"><surname>Bosma</surname><given-names>TL</given-names></name><name name-style="western"><surname>Kurth</surname><given-names>T</given-names></name><name name-style="western"><surname>Isac</surname><given-names>G</given-names></name><name name-style="western"><surname>Chittock</surname><given-names>DR</given-names></name></person-group>. <article-title>Complications of endotracheal intubation in the critically ill</article-title>. <source>Intensive Care Med</source>. (<year>2008</year>) <volume>34</volume>(<issue>10</issue>):<fpage>1835</fpage>&#8211;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-008-1205-6</pub-id><pub-id pub-id-type="pmid">18604519</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmutzhard</surname><given-names>E</given-names></name><name name-style="western"><surname>Pfausler</surname><given-names>B</given-names></name></person-group>. <article-title>Complications of the management of status epilepticus in the intensive care unit</article-title>. <source>Epilepsia</source> (<year>2011</year>) <volume>52</volume>(<issue>Suppl 8</issue>):<fpage>39</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.03233.x</pub-id><pub-id pub-id-type="pmid">21967359</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>CL</given-names></name><name name-style="western"><surname>Spinella</surname><given-names>PC</given-names></name><name name-style="western"><surname>Corsi</surname><given-names>JM</given-names></name><name name-style="western"><surname>Stoltz</surname><given-names>P</given-names></name><name name-style="western"><surname>Zucker</surname><given-names>AR</given-names></name></person-group>. <article-title>Emergent endotracheal intubations in children: be careful if it&#8217;s late when you intubate</article-title>. <source>Pediatr Crit Care Med</source>. (<year>2010</year>) <volume>11</volume>(<issue>3</issue>):<fpage>343</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/PCC.0b013e3181ce6d19</pub-id><pub-id pub-id-type="pmid">20464775</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>T</given-names></name><name name-style="western"><surname>Dass</surname><given-names>M</given-names></name></person-group>. <article-title>Ketamine cystitis: an emerging diagnostic and therapeutic challenge</article-title>. <source>Br J Hosp Med (Lond)</source> (<year>2012</year>) <volume>73</volume>(<issue>10</issue>):<fpage>576</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.12968/hmed.2012.73.10.576</pub-id><pub-id pub-id-type="pmid">23124288</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middela</surname><given-names>S</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>I</given-names></name></person-group>. <article-title>Ketamine-induced vesicopathy: a literature review</article-title>. <source>Int J Clin Pract</source>. (<year>2011</year>) <volume>65</volume>(<issue>1</issue>):<fpage>27</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-1241.2010.02502.x</pub-id><pub-id pub-id-type="pmid">21155941</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Tymowski</surname><given-names>C</given-names></name><name name-style="western"><surname>D&#233;pret</surname><given-names>F</given-names></name><name name-style="western"><surname>Dudoignon</surname><given-names>E</given-names></name><name name-style="western"><surname>Legrand</surname><given-names>M</given-names></name><name name-style="western"><surname>Mallet</surname><given-names>V</given-names></name></person-group><collab>on behalf of the Keta-Cov Research Group</collab>. <article-title>Ketamine-induced cholangiopathy in ARDS patients</article-title>. <source>Intensive Care Med</source>. (<year>2021</year>) <volume>47</volume>(<issue>10</issue>):<fpage>1173</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-021-06482-3</pub-id><pub-id pub-id-type="pmid">34313797</pub-id><pub-id pub-id-type="pmcid">PMC8315088</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>JW</given-names></name><name name-style="western"><surname>Kivovich</surname><given-names>V</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>L</given-names></name></person-group>. <article-title>Ketamine abuse syndrome: hepatobiliary and urinary pathology among adolescents in flushing, NY</article-title>. <source>Pediatr Emerg Care</source>. (<year>2017</year>) <volume>33</volume>(<issue>8</issue>):<fpage>e24</fpage>. <pub-id pub-id-type="doi">10.1097/PEC.0000000000000502</pub-id><pub-id pub-id-type="pmid">26247263</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Excessive activation of NMDA receptors induced neurodevelopmental brain damage and cognitive deficits in rats exposed to intrauterine hypoxia</article-title>. <source>Neurochem Res</source>. (<year>2018</year>) <volume>43</volume>(<issue>3</issue>):<fpage>566</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-017-2451-1</pub-id><pub-id pub-id-type="pmid">29260492</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jevtovic-Todorovic</surname><given-names>V</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>RE</given-names></name><name name-style="western"><surname>Izumi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Benshoff</surname><given-names>ND</given-names></name><name name-style="western"><surname>Dikranian</surname><given-names>K</given-names></name><name name-style="western"><surname>Zorumski</surname><given-names>CF</given-names></name><etal/></person-group><article-title>Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits</article-title>. <source>J Neurosci</source>. (<year>2003</year>) <volume>23</volume>(<issue>3</issue>):<fpage>876</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-03-00876.2003</pub-id><pub-id pub-id-type="pmid">12574416</pub-id><pub-id pub-id-type="pmcid">PMC6741934</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brambrink</surname><given-names>AM</given-names></name><name name-style="western"><surname>Evers</surname><given-names>AS</given-names></name><name name-style="western"><surname>Avidan</surname><given-names>MS</given-names></name><name name-style="western"><surname>Farber</surname><given-names>NB</given-names></name><name name-style="western"><surname>Smith</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Martin</surname><given-names>LD</given-names></name><etal/></person-group><article-title>Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain</article-title>. <source>Anesthesiology</source>. (<year>2012</year>) <volume>116</volume>(<issue>2</issue>):<fpage>372</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1097/ALN.0b013e318242b2cd</pub-id><pub-id pub-id-type="pmid">22222480</pub-id><pub-id pub-id-type="pmcid">PMC3433282</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>TA</given-names></name><name name-style="western"><surname>Paule</surname><given-names>MG</given-names></name><name name-style="western"><surname>Slikker</surname><given-names>W Jr</given-names></name></person-group>. <article-title>Preclinical assessment of ketamine</article-title>. <source>CNS Neurosci Ther</source>. (<year>2013</year>) <volume>19</volume>(<issue>6</issue>):<fpage>448</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1111/cns.12079</pub-id><pub-id pub-id-type="pmid">23462308</pub-id><pub-id pub-id-type="pmcid">PMC6493590</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pisani</surname><given-names>F</given-names></name><name name-style="western"><surname>Cerminara</surname><given-names>C</given-names></name><name name-style="western"><surname>Fusco</surname><given-names>C</given-names></name><name name-style="western"><surname>Sisti</surname><given-names>L</given-names></name></person-group>. <article-title>Neonatal status epilepticus vs recurrent neonatal seizures: clinical findings and outcome</article-title>. <source>Neurology</source>. (<year>2007</year>) <volume>69</volume>(<issue>23</issue>):<fpage>2177</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000295674.34193.9e</pub-id><pub-id pub-id-type="pmid">18056582</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ronen</surname><given-names>GM</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>D</given-names></name><name name-style="western"><surname>Penney</surname><given-names>S</given-names></name><name name-style="western"><surname>Streiner</surname><given-names>DL</given-names></name></person-group>. <article-title>Long-term prognosis in children with neonatal seizures: a population-based study</article-title>. <source>Neurology</source><year>2007</year><volume>69</volume>(<issue>19</issue>):<fpage>1816</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000279335.85797.2c</pub-id><pub-id pub-id-type="pmid">17984448</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>